This interested me FWIW:
A provisional patent application titled “Combination Compositions and Methods for Treatment of Muscular Dystrophy” has been filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs.
A cursory delve into the current patent expiry of one exon skipping drug, Sarepta’s Exondys51, comes up with June 2025 as the patent expiry date, barring an extension.
2044, or an added 19 years of potential protection, has got to be alluring, given 2 years of patent life remaining on Exondys51.
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
This interested me FWIW:A provisional patent application titled...
-
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.7¢ |
Change
0.003(3.57%) |
Mkt cap ! $78.43M |
Open | High | Low | Value | Volume |
8.4¢ | 8.7¢ | 8.4¢ | $72.99K | 855.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 398595 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 0.084 |
3 | 212500 | 0.083 |
2 | 106250 | 0.080 |
2 | 125578 | 0.079 |
1 | 12462 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 398595 | 1 |
0.088 | 400000 | 1 |
0.089 | 135000 | 2 |
0.090 | 794374 | 5 |
0.092 | 50000 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online